Related by context. All words. (Click for frequent words.) 75 carboplatin paclitaxel 75 docetaxel chemotherapy 74 ritonavir boosted 74 neoadjuvant 73 neratinib 73 FOLFIRI 72 CIMZIA TM 72 CA4P 72 estramustine 72 Doxil ® 72 pertuzumab 72 pomalidomide 71 pegylated liposomal doxorubicin 71 alvespimycin 71 mcg kg 71 mapatumumab 71 Pemetrexed 71 phase IIb clinical 71 MAGE A3 ASCI 71 CIMZIA ™ 71 CR# vcMMAE 70 melphalan prednisone 70 chemoradiotherapy 70 fallopian tube cancers 70 relapsed MM 70 bevacizumab Avastin ® 70 recurrent glioblastoma multiforme 70 viral kinetic 70 gemcitabine 70 HuMax EGFr 70 mg/m2 dose 70 sunitinib malate 70 Traficet EN 70 paclitaxel Taxol R 70 FOLPI 70 #mg/m# [001] 70 dacarbazine 70 oral rivaroxaban 70 active comparator 70 Irinotecan 70 Tarceva TM 70 decitabine 70 paclitaxel Taxol 70 administered subcutaneously 70 telaprevir dosed 70 Gemcitabine 70 carboplatin 70 cilengitide 70 FOLFOX4 70 FOLFOX 70 ixabepilone 70 #mg/m# [002] 69 temozolomide 69 phase Ib 69 cisplatin gemcitabine 69 MGd 69 ZACTIMA 69 temsirolimus 69 fosbretabulin 69 bendamustine 69 FOLFOX6 69 teriflunomide 69 adecatumumab 69 alfa 2a 69 Pegasys ® 69 bevacizumab 69 plus ribavirin 69 elotuzumab 69 relapsed ovarian cancer 69 galiximab 69 lenalidomide dexamethasone 69 imetelstat 69 relapsed refractory multiple myeloma 69 docetaxel 69 ribavirin RBV 69 erlotinib Tarceva ® 69 APTIVUS r 69 metastatic renal cell carcinoma 69 Aflibercept 69 sorafenib Nexavar 69 etoposide 69 RG# ITMN 69 gemcitabine Gemzar 69 HGS ETR1 69 PSMA ADC 69 ganetespib 69 vinorelbine 69 subcutaneous SC 69 doxorubicin cyclophosphamide 69 evaluating tivozanib 69 Pegasys plus Copegus 69 Taxotere ® 69 viral kinetics 69 EGFR TKI 69 docetaxel Taxotere 69 pegylated interferon alfa 2b 69 CHOP chemotherapy 69 interferon alfa 2a 68 riociguat 68 5FU 68 axitinib 68 ascending dose 68 HGS ETR2 68 HER2 positive metastatic breast 68 dose cohort 68 vandetanib 68 Peginterferon 68 topotecan 68 mCRC patients 68 DAPT 68 peg interferon 68 goserelin 68 LUX Lung 68 mycophenolate mofetil 68 chemoradiation therapy 68 trastuzumab Herceptin R 68 relapsed myeloma 68 5 FU leucovorin 68 Neoadjuvant 68 HCV RESPOND 2 68 gemcitabine carboplatin 68 Randomized Phase 68 crizotinib PF # 68 docetaxel Taxotere ® 68 Imprime PGG 68 enzastaurin 68 pemetrexed 68 forodesine 68 μg dose 68 CIMZIA TM certolizumab pegol 68 gemcitabine Gemzar ® 68 HCV SPRINT 68 chlorambucil 68 platinum refractory 68 Ceplene/IL-2 68 PEG SN# 68 TACE 68 docetaxel prednisone 68 Panzem R NCD 68 pegylated interferon alfa 2a 68 ZOLINZA 68 Xelox 68 chemoradiation 68 gefitinib Iressa 68 bevacizumab Avastin 68 huN# DM1 68 darunavir ritonavir 68 PEGylated interferon beta 1a 67 daily Infergen 67 intratumoural 67 dasatinib Sprycel ® 67 anti leukemic 67 nonrandomized 67 palifosfamide 67 chemotherapy docetaxel 67 Capecitabine 67 receptor tyrosine kinase inhibitor 67 PREZISTA r 67 standard chemotherapy regimen 67 mg kg dose 67 urate lowering 67 PXD# 67 ELOXATIN 67 phase IIIb 67 5-FU/LV 67 PEGINTRON TM 67 sorafenib Nexavar ® 67 blinded randomized placebo controlled 67 TLK# 67 SCH # 67 Bortezomib 67 recurrent GBM 67 alkylating agent 67 superficial bladder cancer 67 KRN# 67 interferon ribavirin 67 HGS# 67 refractory NSCLC 67 Bezielle 67 PegIFN RBV 67 subcutaneous doses 67 idarubicin 67 Fludara 67 VNP#M 67 Phase Ib II 67 antibody MAb 67 sorafenib tablets 67 fluoropyrimidine 67 multicenter randomized placebo controlled 67 dose cohorts 67 tanespimycin 67 concurrent chemoradiation 67 gemcitabine cisplatin 67 q#h 67 pegylated interferon alpha 67 cyclophosphamide methotrexate 67 QD dosing 67 VELCADE melphalan 67 Insulin PH# 67 TORISEL 67 Pegasys R 67 PEG IFN 67 trabedersen 67 intravitreal injection 67 CoFactor 67 neoadjuvant chemotherapy 67 fluorouracil 67 Folfox 67 paclitaxel carboplatin 67 trastuzumab Herceptin ® 67 plus gemcitabine 67 infusional 67 PegIFN 67 placebo controlled clinical 67 alpha 2a 67 postoperative chemotherapy 67 plus dexamethasone 67 IMC A# 67 sunitinib 67 RSD# oral 67 Phase IIIb clinical 67 docetaxel Taxotere R 67 oral ridaforolimus 67 pharmacodynamic effects 67 Golimumab 67 Cloretazine ® 67 Panzem NCD 67 liposomal formulation 67 mg QD 67 dose escalation 67 YONDELIS 67 ACTEMRA TM 67 peg IFN 67 relapsed CLL 67 PRT# 67 low dose cytarabine 67 cisplatin 67 multicenter Phase II 67 evaluating Xcytrin 67 subcutaneously administered 67 heavily pretreated patients 66 dosage regimens 66 amrubicin 66 5 fluorouracil 66 TO AVOID PREGNANCY WHILE 66 phase IIb study 66 Tyrima 66 #mg BID [003] 66 5 Fluorouracil 66 antiangiogenic therapy 66 relapsed multiple myeloma 66 visilizumab 66 BRIM2 66 Phase 2b study 66 peginterferon alfa 2b 66 ascending doses 66 safety tolerability pharmacokinetics 66 bortezomib 66 dosing cohort 66 dosing regimens 66 cisplatin vinorelbine 66 oral prodrug 66 Taxotere R 66 seliciclib 66 dose regimens 66 CANCIDAS 66 interferon alfa 2b 66 IMGN# 66 Cloretazine 66 multicentre randomized 66 plus prednisone 66 huC# DM4 66 telaprevir dosing 66 doxorubicin docetaxel 66 mRCC 66 paclitaxel Taxol ® 66 placebo controlled Phase 66 Phase Ib clinical 66 pharmacodynamics PD 66 Ranolazine 66 interferon alfa 66 uric acid lowering 66 cyclophosphamide 66 cyclophosphamide doxorubicin vincristine 66 Trastuzumab 66 Peg IFN 66 liposomal doxorubicin 66 ELACYT 66 Pivotal Phase 66 lintuzumab 66 Cloretazine R VNP#M 66 recurrent malignant glioma 66 safety tolerability pharmacokinetic 66 8mg/kg 66 prospectively defined 66 mg m² 66 registrational Phase 66 metastatic CRC 66 adalimumab 66 Xanafide 66 TTF Therapy 66 comparator arm 66 CCX# B 66 Seliciclib 66 monotherapy 66 phase IIb trial 66 mg qd 66 pharmacodynamic profile 66 glufosfamide 66 ibandronate 66 peginterferon alfa 2a 66 tipifarnib 66 Amrubicin 66 antitumor effect 66 Vidaza azacitidine 66 dose dexamethasone 66 ongoing Phase 1b 66 Phase Ib clinical trials 66 mg/m2/day 66 IFN α 66 neoadjuvant treatment 66 Torisel 66 octreotide LAR 66 4mg/kg 66 TELCYTA 66 colesevelam HCl 66 mertansine 66 desvenlafaxine succinate 66 metastatic colorectal carcinoma 66 prucalopride 66 paclitaxel poliglumex 66 randomized Phase III 66 prospective randomized controlled 66 NATRECOR ® 66 IV bolus 66 CLORETAZINE TM VNP#M 66 heavily pretreated 66 celgosivir 66 azacitidine 66 LEXIVA r 66 abiraterone acetate 66 varespladib 66 Platinol ® cisplatin 66 afatinib 66 genotypic resistance 66 dose escalation phase 66 sustained virological response 66 lispro 66 EVIZON 66 #mg QD [002] 66 oblimersen 66 virus HCV protease inhibitor 66 gemcitabine chemotherapy 66 relapsing multiple sclerosis 66 Phase Ib study 66 pegylated interferon alpha 2a 66 vidofludimus 66 assessing T DM1 66 AEG# 66 Aptivus ® 66 lixisenatide 65 bortezomib Velcade 65 Bevacizumab 65 rNAPc2 65 STRIDE PD 65 pharmacokinetics PK 65 Pharmacokinetics PK 65 DFMO 65 CYT# potent vascular disrupting 65 elagolix 65 dosing cohorts 65 5 fluorouracil leucovorin 65 metastatic hormone refractory 65 Gemzar ® 65 lopinavir r 65 cetuximab 65 novel VDA molecule 65 CLARITY study 65 nucleoside analog 65 treatment naive genotype 65 velafermin 65 generation purine nucleoside 65 q8h 65 Allovectin 7 ® 65 abacavir lamivudine 65 aflibercept VEGF Trap 65 dasatinib 65 dose dose escalation 65 pain palliation 65 interferon gamma 1b 65 SAR# [004] 65 metaglidasen 65 azathioprine 65 TMC# C# 65 immunomodulator 65 lenalidomide Revlimid R 65 Darusentan 65 randomized multicenter trial 65 maximally tolerated dose 65 insulin detemir 65 Prospective Randomized 65 mg TID 65 unresectable stage 65 primary hypercholesterolemia 65 pharmacodynamic PD 65 tocilizumab 65 daunorubicin 65 angiogenesis inhibitor 65 Pertuzumab 65 rapid virologic response 65 phase IIa clinical 65 EGFR HER2 65 irbesartan 65 salmeterol fluticasone 65 posaconazole 65 randomized multicenter 65 Omacetaxine 65 irinotecan chemotherapy 65 EURIDIS 65 #I TM# 65 epirubicin 65 tolerability pharmacokinetics 65 sustained virologic response 65 valopicitabine 65 rituximab 65 weekly subcutaneous injections 65 mitoxantrone 65 FOLFOX6 chemotherapy regimen 65 leucovorin 65 Dose Ranging Study 65 glatiramer acetate 65 Xeloda ® 65 tirofiban 65 iniparib 65 dosing intervals 65 neurologic progression 65 PKC# 65 prospective randomized placebo 65 antitumor activity 65 dose cytarabine 65 adalimumab Humira 65 immunomodulatory therapy 65 flutamide 65 trabectedin 65 romidepsin 65 BRAF inhibitor 65 remission CR 65 APTIVUS 65 Dacogen injection 65 metastatic HRPC 65 Pegylated Interferon 65 adjuvant radiation 65 cell lymphoma CTCL 65 Enzastaurin 65 #mg dose [003] 65 intravenous dosing 65 mcg albinterferon alfa 2b 65 peginterferon 65 tipranavir 65 lapatinib Tykerb 65 Copegus ribavirin 65 subcutaneous formulation 65 trastuzumab 65 Randomized Phase II 65 milatuzumab 65 MIRCERA 65 gout flares 65 adriamycin 65 evaluable subjects 65 rt PA 65 intermittent dosing 65 pharmacodynamic properties 65 XELOX 65 randomized controlled Phase 65 Elotuzumab 65 stage IIIB 65 Monotherapy 65 metastatic castration resistant 65 metastatic RCC 65 double blinded placebo 65 pan HDAC inhibitor 65 SABCS 65 Randomized Double blind 65 saline placebo 65 nitazoxanide 65 bevacizumab Avastin R 65 Phase Ib 65 Chemophase 65 resectable pancreatic cancer 65 AAG geldanamycin analog 65 orally administered inhibitor 65 NATRECOR R 65 clodronate 65 rituximab Rituxan 65 certolizumab 65 xenograft models 65 obatoclax 65 placebo controlled randomized 65 randomized blinded 65 multicenter Phase III 65 sorafenib 65 phase IIb 65 FOLPI regimen 65 biochemical relapse 65 talabostat 65 Cytoxan 65 vinca alkaloid 65 PSN# [002] 65 sapacitabine 65 Oral Fingolimod 65 boosted protease inhibitor 65 luteinizing hormone releasing 65 OncoVEX GM CSF 65 metastatic GIST 65 anthracycline taxane 65 Acute Ischemic Stroke 65 cediranib 65 Targretin 65 aflibercept 65 vorinostat 65 biologic therapy 65 adjuvant therapy 65 sunitinib Sutent ® 65 Hormone Refractory Prostate Cancer 65 zoledronic acid 65 debulking surgery 65 AEGR 65 TELINTRA 65 subcutaneous dose 65 tolerated dose MTD 65 edoxaban 65 pegylated interferon 65 Pivotal Phase III 64 regorafenib 64 Degarelix 64 FUSILEV enhances 64 Metabolic Efficiency 64 brivaracetam 64 capecitabine Xeloda 64 Dasatinib 64 Fluorouracil 64 multicenter Phase 64 blinded randomized 64 TAXOTERE R 64 refractory multiple myeloma 64 farletuzumab 64 HRPC 64 DOXIL 64 favorable pharmacokinetic profile 64 capecitabine Xeloda R 64 insulin degludec 64 erlotinib 64 efficacy tolerability 64 neoadjuvant therapy 64 Tanespimycin 64 chemotherapy FOLFOX 64 PNP inhibitor 64 Phase 2a trial 64 Cyclophosphamide 64 oral deforolimus 64 icatibant 64 Fulvestrant 64 NSABP B 64 cisplatin chemotherapy 64 Triapine R 64 ON #.Na 64 investigational humanized monoclonal antibody 64 investigational monoclonal antibody 64 secondary efficacy endpoints 64 Phase 1b trial 64 peginterferon alpha 2a 64 RG# [001] 64 dose escalation trial 64 ULORIC 64 resistant ovarian cancer 64 Neulasta ® 64 tacrolimus ointment 64 Telintra 64 Phase 1b 64 pegylated interferon alfa 64 cetuximab Erbitux R 64 pharmacokinetic PK 64 antitumor effects 64 paclitaxel cisplatin 64 Maximum Tolerated Dose MTD 64 Peginterferon Alfa 2a 64 ritonavir boosted atazanavir 64 resminostat 64 LY# [003] 64 Cisplatin 64 Sandostatin R 64 azacytidine 64 registrational trial 64 Onrigin 64 GnRH agonists 64 custirsen 64 eptifibatide 64 endothelin antagonists 64 prospective multicenter 64 EFAPROXYN 64 EOquin TM 64 plasma kallikrein inhibitor 64 relapsed MCL 64 OXi# 64 bolus dose 64 alefacept 64 placebo controlled Phase III 64 CBLC# 64 CALGB # [002] 64 teduglutide 64 Placebo Controlled Trial 64 ribavirin USP 64 oral FTY# 64 liposomal amphotericin B 64 coadministration 64 dexamethasone Decadron 64 mg administered orally 64 PROMACTA 64 analgesic efficacy 64 INC# 64 ExTRACT TIMI 64 platelet inhibitor 64 DU #b 64 TMC# r 64 randomized Phase IIb 64 Meets Primary Endpoint 64 R# #mg BID 64 eniluracil 64 nadolol 64 Phase IIB 64 zalutumumab 64 octreotide acetate 64 mitomycin 64 imatinib Gleevec 64 refractory CLL 64 rFVIIa 64 T#I [002] 64 GFT# 64 thymalfasin 64 angiotensin receptor blocker ARB 64 prospectively randomized 64 PRADAXA 64 Pharmacokinetic 64 IFN alfa 64 Vidaza ® 64 Adalimumab 64 refractory AML 64 Proxinium TM 64 mg BID 64 Carfilzomib 64 ZD# [001] 64 irinotecan doxorubicin oxaliplatin paclitaxel 64 histone deacetylase HDAC inhibitor 64 oral allopurinol 64 double blinded randomized 64 fulvestrant 64 cetuximab Erbitux 64 Camptosar ® 64 noninferiority 64 octreotide 64 XL# SAR# 64 DAVANAT 64 Initiate Phase 64 REVLIMID lenalidomide 64 remission induction 64 multicenter randomized 64 randomized #:# 64 GAMMAGARD 64 APPRAISE 64 thalidomide Thalomid 64 Navelbine ® 64 capecitabine 64 inhibitor RG# 64 cetuximab Erbitux ® 64 dosed orally 64 ARIKACE 64 lapatinib 64 Omacetaxine mepesuccinate 64 pegfilgrastim 64 Quinamed 64 odanacatib 64 INCB# [001] 64 AVADO 64 olaparib 64 BENICAR HCT 64 colorectal liver metastases 64 limiting toxicity 64 HBeAg positive patients 64 Epirubicin 64 refractory chronic lymphocytic 64 idraparinux 64 tipranavir r 64 AKT inhibitor 64 Phase IIIb 64 CCX# 64 PROSTVAC ® 64 mg/m2 IV 64 infusional 5-FU/LV 64 dose escalation clinical 64 Dual Opioid 64 EndoTAGTM 1 64 omega interferon 64 AZILECT R 64 GW# [003] 63 pharmacodynamic markers 63 KRAS mutations occur 63 AIR CF1 63 Herceptin trastuzumab 63 CLL SLL 63 ATACAND 63 proteasome inhibitor bortezomib 63 oral diclofenac 63 optimal dosing 63 orally dosed 63 FOLFIRI chemotherapy 63 PREZISTA rtv 63 MabCampath 63 investigational protease inhibitor 63 Phase IIa trial 63 EndoTAG TM -1 63 tolvaptan 63 Tarceva erlotinib 63 protease inhibitor PI 63 dexpramipexole 63 Sustained Virological Response 63 Sandostatin LAR Depot 63 DEB# 63 randomized multicenter Phase III 63 NCCTG 63 plus methotrexate 63 biologic DMARD 63 multicenter randomized controlled 63 letrozole Femara 63 rosuvastatin #mg 63 intravenously administered 63 nilotinib 63 cis retinoic acid 63 catheter occlusion 63 BMS # 63 Natalizumab 63 Randomised 63 subcutaneous dosing 63 antiviral efficacy 63 somatostatin analog 63 TYKERB 63 cancer mCRC 63 Zybrestat 63 paclitaxel 63 TG# [003] 63 Pralatrexate 63 lesinurad 63 MEND CABG II 63 ADVANCE PD 63 PEGylated Fab fragment 63 Vicinium TM 63 Pegylated Liposomal Doxorubicin 63 glycoprotein IIb IIIa inhibitor 63 zonisamide SR 63 adjuvant chemotherapy 63 fluorouracil leucovorin 63 Ceflatonin 63 continuous intravenous infusion 63 vismodegib 63 dose limiting toxicities 63 CYC# 63 GMX# 63 subcutaneous injections 63 piperacillin tazobactam 63 dacetuzumab 63 ug dose 63 TASKi2 63 metreleptin 63 alpha 2b 63 Sorafenib 63 mGluR5 negative 63 dosing schedules 63 lumiliximab 63 intravenous bisphosphonates 63 temsirolimus Torisel ® 63 Fludarabine 63 Gliadel Wafer 63 metastatic malignant 63 gemtuzumab ozogamicin 63 chemo radiotherapy 63 PDX pralatrexate 63 tesmilifene 63 Capesaris 63 IIIa inhibitor 63 HSP# inhibitor 63 cytarabine 63 Targretin capsules 63 bosentan 63 antiarrhythmic drug 63 PROVENGE sipuleucel T 63 CD3 monoclonal antibody 63 FOLFOX chemotherapy 63 antiplatelet agent 63 GSK# [001] 63 telaprevir VX 63 antiangiogenic 63 evaluating satraplatin 63 ofatumumab 63 Zevalin R Ibritumomab 63 Decitabine 63 Initiated Phase 63 leukemia AML 63 corticosteroid dexamethasone 63 thromboembolic events 63 Pharmacokinetic Study 63 oral Xeloda 63 rHuPH# 63 limiting toxicity DLT 63 serum phosphorous 63 cytokine refractory 63 Solid Tumors 63 Glufosfamide 63 efficacy endpoint 63 virological response 63 pCR 63 ALA PDT 63 BAY #-# 63 masked placebo controlled 63 Dapagliflozin 63 RezularTM 63 DLTs 63 imatinib therapy 63 IL# PE#QQR 63 chemotherapy cisplatin 63 edifoligide 63 sipuleucel T 63 tumor necrosis 63 standard chemotherapy regimens 63 mg/m2 administered 63 busulfan 63 lymphoma CTCL 63 Platinol 63 Navelbine 63 GnRH agonist 63 INCB# [003] 63 GVAX 63 metformin sulfonylurea 63 IMA# 63 mg RDEA# 63 oral chemotherapeutic agent 63 receiving INTRON 63 Teriflunomide 63 composite endpoint 63 GP IIb IIIa inhibitor 63 apremilast 63 PRECiSE 63 Phase 2b trial 63 refractory CTCL 63 follicular NHL 63 VFEND 63 severe neutropenia 63 OMP #M# 63 mcg doses 63 ARB telmisartan 63 FOLFOX regimen 63 cardiac toxicity 63 EGFR expressing mCRC 63 taxane chemotherapy 63 dextromethorphan quinidine 63 histone deacetylase inhibitor 63 metastatic malignant melanoma 63 REOLYSIN ® 63 BEACOPP 63 cilostazol 63 Phase IIa trials 63 dacarbazine DTIC 63 patients evaluable 63 castrate resistant prostate cancer 63 Melphalan 63 APOPTONE 63 Ixempra 63 atacicept 63 #mg QD [001] 63 randomized #:#:# 63 APTIVUS ritonavir 63 budesonide foam 63 prospective multicenter randomized 63 trastuzumab DM1 63 dose melphalan 63 RRMS patients 63 Phase 1b clinical 63 FEMALES SHOULD BE ADVISED 63 PA# [002] 63 paclitaxel eluting stents 63 placebo controlled studies 63 mitoxantrone plus 63 Betaferon ® 63 Metastatic Melanoma 63 potent CYP#A# inhibitors 63 Flu Cy 63 DMARD 63 PRE SURGE 63 Arikace 63 taxane resistant 63 Apoptone 63 systemic ALCL 63 ZYBRESTAT fosbretabulin 63 #mg BID [001] 63 LHRH receptor positive 63 unfractionated heparin UFH 63 Phase #b/#a trial 63 HCD# [002] 63 Carboplatin 63 ceftazidime 63 anthracycline chemotherapy 63 verteporfin 63 ISTODAX 63 pegylated liposomal doxorubicin PLD 63 clomipramine 63 ORENCIA ® 63 KRAS status 63 noninferior 63 deforolimus 63 weekly intravenous infusions 63 Pegasys peginterferon alfa 2a 63 GOUT 63 PEGPH# 63 ENMD # 63 locoregional recurrence 63 Hsp# Inhibitor 63 Ozarelix 63 atazanavir ritonavir 63 dose titration 63 naïve HCV 63 Sapacitabine 63 virologic response 63 indibulin 63 virologic failure 63 resectable 63 pegylated interferon peg IFN 62 aspirin clopidogrel 62 pharmacodynamic 62 low dose dexamethasone 62 trastuzumab Herceptin 62 TACI Ig 62 AVOREN 62 ACTEMRA 62 Ophena TM 62 nicardipine 62 #mg q8h 62 COPEGUS 62 mcg dose 62 Hycamtin 62 Laquinimod 62 Asentar 62 Controlled Trial 62 androgen independent 62 aplindore 62 Dacogen decitabine 62 MGCD# [001] 62 intravesical infusion therapy 62 daclizumab 62 ribavirin therapy 62 gefitinib 62 systemic RNAi therapeutic 62 Metastatic Colorectal Cancer 62 ara C 62 mcg BID 62 Pazopanib 62 LPV r 62 perifosine 62 GRN#L 62 papillary renal cell carcinoma 62 velafermin belinostat 62 olmesartan 62 intravenous IV infusion 62 C1 INH 62 orally bioavailable 62 NVA# 62 insulin lispro 62 doripenem 62 tolerability 62 phase IIa 62 placebo dexamethasone 62 mg/m2 62 microgram kg 62 paclitaxel chemotherapy 62 raltegravir 62 Vitaxin 62 phase Ib clinical 62 Azixa 62 selective modulator 62 vicriviroc 62 dose escalation Phase 62 IIa trial 62 Azacitidine 62 TriRima 62 achieved CCyR 62 Aplidin R 62 Taxotere docetaxel 62 Cimzia TM 62 bicifadine 62 rindopepimut 62 oral antiviral 62 AVASTIN